Psilocybin-assisted psychotherapy for Parkinson's disease without depression: A case-report
Journal of Parkinson s Disease,
Год журнала:
2025,
Номер
unknown
Опубликована: Фев. 2, 2025
Background
Psychedelic
assisted
psychotherapy
(PAP)
can
improve
treatment-resistant
depression.
Its
usefulness
in
Parkinson's
disease
(PD)
is
unknown.
PD
patients
may
have
problems
adjusting
to
their
chronic
progressive
neurological
disease.
A
change
from
emotional
avoidance
acceptance
has
been
reported
following
psilocybin
administration
with
Objective
To
report
for
the
first
time
effect
of
a
patient.
Methods
non-depressed
43-year-old
female
2-year
history
presented
difficulty
PD,
anxious
ruminations
and
pessimism.
The
patient
declined
an
increase
dopaminergic
medication
or
introduction
anxiolytic.
Therapeutic
education
was
not
beneficial.
received
four
sessions
high-dose
PAP
within
one
year.
Neurological
psychiatric
assessments
were
performed
before
at
year
follow-up
using
qualitative
interviews
quantitative
assessment
motor
status,
dispositional
optimism,
depression,
anxiety,
apathy,
well-being.
Results
well
tolerated.
It
significantly
improved
patient's
overall
pessimistic
outlook
on
her
future
decreased
worries
about
potential
handicap
due
PD.
Her
general
well-being
improved,
as
all
psychometric
scores
except
apathy
scale.
Motor
status
remained
unchanged.
Better
allowed
accept
pharmacological
treatment
adjustment.
Conclusions
could
be
safe
useful
pessimism
difficulties
accepting
by
promoting
profound
decentration
habitual
thoughts
emotions,
improving
mood
acceptance.
Randomized,
controlled
studies
are
needed
confirm
this
result.
Язык: Английский
Exploring novel therapeutic strategies: Could psychedelic perspectives offer promising solutions for Alzheimer’s disease comorbidities?
Dialogues in Clinical Neuroscience,
Год журнала:
2025,
Номер
27(1), С. 1 - 12
Опубликована: Март 19, 2025
The
increasing
prevalence
of
dementia
within
an
ageing
global
population,
combined
with
prolonged
life
expectancy,
accentuates
Alzheimer's
disease
(AD)
as
a
multifaceted
healthcare
challenge.
This
challenge
is
further
compounded
by
the
limited
therapeutic
options
currently
available.
Addressing
intricacies
AD
management,
mitigation
comorbidities
has
emerged
pivotal
facet
treatment.
Comorbid
conditions,
such
neurobehavioral
symptoms,
play
role
in
shaping
clinical
course,
and
outcomes
this
pathology;
highlighting
importance
comprehensive
care
approaches
for
affected
individuals.
Exploration
psychedelic
compounds
psychiatric
palliative
settings
recently
uncovered
promising
potential,
enhancing
neuroplasticity,
emotional
processing
connection.
These
effects
are
particularly
relevant
context
AD,
where
therapy
offers
hope
not
only
mitigating
core
symptoms
but
also
addressing
array
associated
condition.
integration
method
chance
to
significantly
enhance
provided
those
navigating
intricate
landscape
AD.
Therefore,
current
paper
reviews
link
between
more
frequent
additional
health
conditions
that
may
coexist
dementia,
explores
potential
these
concurrent
conditions.
Язык: Английский
Mushrooms, Microdosing, and Mental Illness: The Effect of Psilocybin on Neurotransmitters, Neuroinflammation, and Neuroplasticity
Neuropsychiatric Disease and Treatment,
Год журнала:
2025,
Номер
Volume 21, С. 141 - 155
Опубликована: Янв. 1, 2025
The
incidence
of
mental
health
disorders
is
increasing
worldwide.
While
there
are
multiple
factors
contributing
to
this
problem,
neuroinflammation
underlies
a
significant
subset
psychiatric
conditions,
particularly
major
depressive
and
anxiety
disorders.
Anti-inflammatory
interventions
have
demonstrated
benefit
in
these
conditions.
Psilocin,
the
active
ingredient
mushrooms
Psilocybe
genus,
both
potent
serotonin
agonist
anti-inflammatory
agent,
increases
neuroplasticity,
decreases
overactivity
default
mode
network.
Studies
using
hallucinogenic
doses
psilocin
under
supervision
therapist/guide
consistently
benefits
individuals
with
depression
end-of-life
anxiety.
Microdosing
psilocybin
sub-hallucinogenic
has
also
mood
disorders,
may
offer
safe,
less
expensive,
more
available
alternative
full
for
as
well
other
medical
conditions
which
inflammation
principal
pathophysiology.
Язык: Английский
Exploring psilocybin’s role in mental health and palliative medicine: a path to improved well-being
Expert Opinion on Emerging Drugs,
Год журнала:
2025,
Номер
unknown
Опубликована: Апрель 3, 2025
Although
long
known
for
their
psychoactive
effects,
psychedelic
drugs
have
only
recently
been
investigated
medicinal
use.
Psilocybin
has
attracted
the
greatest
interest
with
studies
suggesting
that
it
may
be
a
useful
agent
in
psychiatry
and
palliative
care.
Clinical
trials
included
psilocybin
were
searched
PubMed,
Embase,
ClinicalTrials.gov,
demonstrating
adult
care
are
medical
fields
show
treatment.
is
powerful
drug
needs
to
used
caution
but
benefit
some
patients,
including
when
other
options
failed.
It
best
evidenced
treatment
resistant
depression
care,
where
patients
usually
treated
specialist
centers.
novel
mechanism
of
action,
targeting
5HT2A
receptor,
can
rapid
onset
action.
There
many
questions
regarding
its
use
remain
clarified,
efficacy
indications
role
as
adjunctive
psychotherapy.
The
psychoactive,
or
effects
well
documented,
clinical
importance
disputed.
Язык: Английский
Advancements in Neurotechnology: Pioneering Brain Monitoring and Stimulation for Enhanced Treatment and Understanding
ACS Medicinal Chemistry Letters,
Год журнала:
2024,
Номер
16(1), С. 20 - 22
Опубликована: Дек. 18, 2024
This
Patent
Highlight
explores
recent
innovations
in
neuroscience
and
neurotechnology,
particularly
brain
monitoring
stimulation.
It
examines
four
essential
patents:
novel
psychoplastogens
for
neuronal
growth,
techniques
transferring
emotional
states,
advanced
systems
self-guided
neural
diagnostics
treatment.
The
discussion
extends
to
deep
stimulation
(DBS)
motor
memory
disorders,
enhanced
function
through
electroencephalography
(EEG),
the
role
of
artificial
intelligence
personalizing
treatment
strategies.
These
advancements
represent
a
pivotal
development
introducing
innovative
methodologies
elucidating
neurological
mechanisms,
addressing
psychiatric
augmenting
cognitive
function.
Язык: Английский
Advances in Psychoactive Alkaloid Delivery, Ergoline Analogues, and Serotonin Receptor Modulation for Enhanced Therapeutic Outcomes
ACS Medicinal Chemistry Letters,
Год журнала:
2024,
Номер
16(1), С. 26 - 28
Опубликована: Дек. 18, 2024
Recent
advancements
in
pharmaceutical
research
have
focused
on
developing
novel
psychoactive
compounds
and
receptor
modulators
that
enhance
therapeutic
outcomes
while
minimizing
adverse
effects.
This
Patent
Highlight
examines
three
innovative
approaches:
(1)
transmucosal
delivery
of
dephosphorylated
alkaloids,
(2)
nonhallucinogenic
serotonin
modulators,
(3)
ergoline
analogues
designed
for
treating
neurological
disorders.
These
innovations
offer
breakthroughs
drug
delivery,
targeting,
structural
modifications,
aiming
to
address
challenges
the
treatment
mood
disorders,
diseases,
chronic
pain
improving
bioavailability
reducing
side
effects
hallucinogenic
properties.
Язык: Английский
Advances in Psychedelic Therapeutics: Novel Prodrugs and Derivatives for Enhanced Mental Health Treatment
ACS Medicinal Chemistry Letters,
Год журнала:
2024,
Номер
15(12), С. 2071 - 2073
Опубликована: Ноя. 11, 2024
Recent
innovations
in
psychedelic
research
have
led
to
the
development
of
novel
compounds
designed
enhance
therapeutic
potential
psilocin
and
related
tryptamines.
This
Patent
Highlight
reviews
three
essential
patents
that
focus
on
improving
stability,
bioavailability,
efficacy
these
for
treating
mental
health
disorders
such
as
depression,
anxiety,
substance
use
disorders.
The
compounds─4-pivaloyloxy-N-methyltryptammonium
chloride,
alkyl
quaternary
ammonium
tryptamines,
4-pivaloyloxy-N-methyltryptammonium
derivatives─represent
significant
advancements
field
psychedelic-assisted
therapy.
These
offer
new
hope
more
reliable
effective
treatments,
particularly
addressing
limitations
associated
with
traditional
psychedelics.
findings
from
preclinical
studies
support
play
a
vital
role
treatment
neurological
Язык: Английский